Plaque regression and stabilization by proprotein convertase subtilisin/kexin type 9 inhibitors: a meta-analysis of intravascular imaging studies.
Coron Artery DisJul 29, 2026 (epub)
Clinical ResearchCardiology
Ryu Umezono, Shingo Kato, Naofumi Yasuda et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on coronary atherosclerotic plaques using intravascular imaging. Involving 1642 patients across ten studies, the analysis found that PCSK9 inhibitors significantly reduced percent atheroma volume (PAV) by 1.03% compared to controls, indicating both plaque regression and stabilization.
Key findings
- PCSK9 inhibitors reduced percent atheroma volume (PAV) by 1.03% compared to control.
- Minimum fibrous cap thickness increased by 28.44 µm with PCSK9 inhibitors.
- PCSK9 inhibitors decreased maximum lipid core burden index (maxLCBI 4 mm) by 39.73.
Why it matters
Understanding the impact of PCSK9 inhibitors on plaque characteristics is crucial for clinicians, as these changes may contribute to improved cardiovascular outcomes and inform treatment strategies for patients with atherosclerosis.